STAAR Surgical (NASDAQ: STAA) reported Q2 EPS of $0.04, $0.08 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $23.5 million versus the consensus estimate of $21.45 million.

Third Quarter 2017 Overview

• Quarterly Net Sales of $23.5 Million Up 17% from the Prior Year Quarter
• ICL Sales Up 22% and Units Up 18% from the Prior Year Quarter
• IOL Sales Down 16% and Units Down 6% from the Prior Year Quarter
• Gross Margin at 71.8% of Sales from 74.2% of Sales in the Prior Year Quarter due to Larger Volume of Lower Margin Injector Sales
• Quarterly Net Earnings per Share of $0.03 vs. Prior Year Quarter Net Loss of ($0.04) per Share
• Cash, Cash Equivalents and Restricted Cash Ended the Quarter at $16.3 Million
• Signed New and Extended Existing Strategic Agreements with Providers in China, Korea, Europe
• Continued First-in-Man Clinical Evaluation of EVO Visian ™ Implantable Collamer Lenses with EDOF for Presbyopia Correction – EU Clinical Study to Commence in Q1 2018

For earnings history and earnings-related data on STAAR Surgical (STAA) click here.